Raymond James Financial
RXST icon

Raymond James Financial’s RxSight RXST Stock Holding History

Raymond James Financial’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,132
Closed -$27.7K – 6412
2025
Q2 		$27.7K Buy
+2,132
New +$32.1K ﹤0.01% 5454

Other funds holding RXST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's RXST Position: Q3 2025 in Review

Raymond James Financial sold out of RxSight (RXST) in Q3 2025, closing a stake of 2,132 shares — an estimated $27.7K sold.

Raymond James Financial first reported a position in RXST in Q2 2025 and held it in 1 quarter. The position peaked at $27.7K in Q2 2025. 160 funds tracked by Wall St. Rank hold RXST as of Q3 2025.

  • Raymond James Financial reported no remaining RxSight position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,132 RxSight shares in Q3 2025, an estimated $27.7K.
  • Raymond James Financial first reported a position in RxSight in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's RxSight position peaked at $27.7K in Q2 2025.
  • 160 funds tracked by Wall St. Rank held RxSight as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.